David Schofield and his colleagues review the potential and use of phages as specific tools to identify bacterial pathogens in clinical specimens.
Phage diagnostics can rapidly and sensitively detect their specific host in a variety of culture, food, water, clinical and environmental matrices. Despite these attributes, there are only a few phage diagnostic technologies currently used in the clinical field to detect Mycobacterium tuberculosis, Yersinia pestis, Bacillus anthracis, and Straphylococcus aureus.
While no other phage products appear to be currently used in clinical diagnostic laboratories, wild-type phages, genetically engineered phages and phage components are being evaluated as potential bacterial detectors in research and development laboratories. Most of this research is directed toward the detection of food-borne pathogens in various food matrices. The VIRCA (Virus Resistant Cassava for Africa) project was conceived in 2005 as an initiative to bring effective solutions to the viral diseases that suppress cassava (Manihot esculenta) yields and reduce farmer incomes in East Africa. Based entirely within public sector research organizations, the project's goal is to develop the intellectual and technical capacity to improve cassava varieties for resistance to cassava brown streak disease (CBSD) and cassava mosaic disease (CMD) and to field test, obtain regulatory approval and deliver these products to small landholder farmers. No financial profit is intended for the technology developers. VIRCA's strategies for generating resistance to CMD and CBSD are based on pathogen-derived RNAi technology and will develop two products. First will be the cultivar TME204 modified for resistance to CBSD and second, Ebwanateraka modified for resistance to both CBSD and CMD.
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